AI Summary
This grant opportunity, PAR-25-059 (CFDA: 93.853), seeks to fund innovative projects focused on assay development and neurotherapeutic agent identification. The IGNITE program aims to nurture initial translational efforts, but clinical trials are not allowed under this R61/R33 mechanism.